Takeda and Hyderabad-based vaccine maker Biological E. have formed a strategic partnership to accelerate access to the Japanese biopharmaceutical major’s QDENGA dengue vaccine (TAK-003) multi-dose vials.
BE will ramp up to a manufacturing capacity of up to 50 million doses a year, accelerating Takeda’s efforts to manufacture 100 million doses a year within the decade, the firms said on their partnership that was announced in the presence of Chief Minister A. Revanth Reddy at BioAsia 2024 inaugural session in Hyderabad on Tuesday.
Their partnership will build upon existing manufacturing capacity for the vaccine at Takeda’s facility in Singen, Germany and Takeda’s long-term partnership with IDT Biologika GmbH, a joint statement said. QDENGA is a dengue tetravalent live, attenuated vaccine, also known as TAK-003, is currently available for children and adults in the private market in countries in Europe, Indonesia and Thailand and in private and some public programmes in Argentina and Brazil. TAK-003 is not approved for use in India.
